DUBLIN--(BUSINESS WIRE)--The "2018 Post Operative Nausea And Vomiting Drug Development- Pipeline Analysis Report" report has been added to ResearchAndMarkets.com's offering.
Around 10 companies and universities are focusing on developing treatment options for Post Operative Nausea and Vomiting.
This report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.
Current status, developmental phase, participating companies and entities, recent developments, orphan drug/ fast track/ other designations, drug class are provided for each Post Operative Nausea and Vomiting pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.
In addition to complete details of each product, the report provides key trends in Post Operative Nausea and Vomiting pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
- Albireo AB
- Arena Pharmaceuticals
- CymaBay Therapeutics
- Enanta Pharmaceuticals
- FF Pharma
- Intercept Pharmaceuticals
- KAN Research Institute
- NGM Biopharmaceuticals
- Phenex Pharmaceuticals
- Suzhou Zelgen Biopharmaceutical Co Ltd
- Tiziana Life Sciences
- Virobay Inc
- Zydus Cadila
Key Topics Covered
1 Table of Contents
2 Post Operative Nausea and Vomiting Pipeline Analysis
3 Post Operative Nausea and Vomiting - Company-wise Pipeline Analysis
4 Post Operative Nausea and Vomiting R&D Pipeline Snapshots
5 Recent Developments in Post Operative Nausea and Vomiting Pipeline
For more information about this report visit https://www.researchandmarkets.com/research/9hzfpf/post_operative?w=4